Retatrutide, Foundayo, and the Next Era of Obesity Medicine
For decades, I have worked with individuals trying to improve their health, energy, function, and quality of life through changes in nutrition, physical activity, behavior, and lifestyle. Long before I became a physician, I was helping people navigate weight management and the challenges that often accompany it.
During much of that time, one of the central questions in obesity medicine was whether we could achieve meaningful and sustained weight loss with medication.
That question has changed.
The emergence of Foundayo (orforglipron) and the investigational therapy retatrutide signals something larger than the arrival of two new medications. They represent another step in the evolution of obesity treatment and, perhaps more importantly, a shift in what we need to focus on next.
The question is no longer simply whether these medications work.
Increasingly, the question is whether we can build the systems, support structures, and care models that help people use them safely, successfully, and sustainably.
Two medications. Two different signals.
Foundayo (orforglipron) recently became the first approved oral, non-peptide GLP-1 receptor agonist for chronic weight management. Unlike injectable therapies, it is taken as a daily pill and does not require the food and water restrictions associated with earlier oral GLP-1 medications.
That may sound like a convenience feature.
It may prove to be much more than that.
For many patients, an effective oral option has the potential to lower barriers to treatment, expand access, and normalize obesity care in settings where injections may be less acceptable or less practical.
Retatrutide remains investigational, but the recently announced Phase 3 topline results have generated significant excitement throughout obesity medicine. Retatrutide targets three metabolic pathways simultaneously: GLP-1, GIP, and glucagon receptors.
The reported weight-loss outcomes are among the most substantial seen to date with a medication and approach those historically seen with some bariatric procedures. These results are based on topline data that have not yet undergone peer review or publication, and that distinction remains important. At the same time, the findings suggest that we may be entering a new phase in the treatment of obesity and related metabolic disease.
One medication may expand access.
The other may expand what is possible.
Both deserve attention.
What I believe is the bigger story
As impressive as these medications are, I do not believe the most important story is the medications themselves.
The bigger story is what they reveal about where obesity medicine is headed.
For years, conversations about obesity often became polarized.
Some viewed obesity primarily as a matter of willpower.
Others viewed it solely through a medical lens.
The reality has always been more complex.
Obesity is influenced by biology, environment, psychology, behavior, culture, economics, relationships, sleep, stress, medications, health conditions, and countless other factors.
That complexity is one reason so many people have struggled.
It is also one reason simplistic solutions have consistently fallen short.
What keeps me optimistic is not simply the arrival of more effective therapies.
It is the possibility that obesity will increasingly be treated like the chronic, multifactorial disease it is—with better science, better tools, greater compassion, and more individualized support.
The medications matter.
The people living with obesity matter more.
What I see in practice
One of the most common reactions I see when effective treatment begins working is relief.
It is not because the medication does all the work.
It is not because the journey suddenly becomes easy.
It is because many individuals experience, sometimes for the first time, a reduction in the biological forces that feel like they have been working against them for years.
Many have spent decades blaming themselves.
Many have been told, directly or indirectly, that they simply needed more discipline, more motivation, or more willpower.
Yet when biology feels more supportive of their goals, something interesting often happens.
The motivation was there all along.
The effort was there all along.
The challenge was that the biological burden was greater than many people realized.
That does not mean medications replace health-promoting behaviors.
It means healthy behaviors often become more achievable.
The goal is not weight loss alone
One of the risks of the current conversation is that weight loss becomes the only outcome people pay attention to.
Weight loss matters.
But for most patients, it is not the ultimate goal.
For many, the real goal is a better quality of life.
They want to play with their children or grandchildren without becoming exhausted.
They want to travel more comfortably.
They want less knee pain.
They want to move more easily.
They want more energy at the end of the day.
They want to reduce their risk of future disease.
They want greater confidence.
They want more years doing the things they love with the people they care about.
Health-promoting weight loss may help create those outcomes.
But it is rarely the outcome people care about most.
The goal is better health.
The goal is improved function.
The goal is preserving muscle while reducing excess adiposity.
The goal is improving metabolic health.
The goal is increasing quality of life.
Weight loss is often part of the journey.
It should not be confused with the destination.
What primary care clinicians should understand
Primary care is likely to play an even larger role in obesity treatment over the coming decade.
As treatment options expand, more patients will seek care in primary care settings, where long-term relationships and continuity of care already exist.
Oral therapies such as Foundayo may help reduce barriers for some individuals who are hesitant about injections or who prefer the simplicity of a daily pill.
At the same time, obesity remains a chronic disease requiring longitudinal management.
Prescribing may become easier.
Supporting long-term success may become more complex.
Clinicians will increasingly need systems that support nutritional adequacy, muscle preservation, physical activity, behavioral health, adverse-event management, medication transitions, and long-term follow-up.
The prescription is only one component of the treatment plan. And it may need to change in the future.
What employers should understand
Many employers still view GLP-1 therapies primarily through the lens of pharmacy costs.
That perspective is becoming increasingly incomplete.
Most employers do not actually want weight loss.
They want the outcomes that may accompany improved health:
Lower healthcare expenditures.
Reduced disability.
Improved productivity.
Greater engagement.
Better retention.
A healthier and more resilient workforce.
The medications may help create those outcomes.
The question is whether the surrounding system helps sustain them.
Organizations that focus exclusively on medication coverage may achieve short-term weight loss.
Organizations that also invest in education, nutrition, physical activity, behavioral support, engagement, and long-term follow-up are more likely to achieve durable health improvements.
This is one of the lessons bariatric surgery taught us decades ago.
The procedure matters.
The support structure matters too.
What obesity specialists should be thinking about
Obesity medicine is entering a fascinating period.
We now have therapies capable of helping many people achieve levels of weight loss that were previously difficult to achieve without surgery.
The next set of questions may be even more important.
How do we preserve lean mass?
How do we help patients maintain strength and function?
How do we reduce unstructured discontinuation?
How do we support people through interruptions in treatment?
How do we help patients transition between therapies?
How do we integrate pharmacotherapy with nutrition, exercise, behavioral health, procedures, surgery, and community support?
How do we sustain health improvements over years and decades rather than months?
These questions may ultimately influence outcomes as much as the medications themselves.
What I believe the next frontier will be
One of the lessons I keep returning to—whether I am working with an individual patient, building a clinical program, advising an employer, collaborating with a health system, or helping design a digital health solution—is that outcomes rarely depend on a single intervention.
They emerge from systems.
The medication matters.
Nutrition matters.
Physical activity matters.
Sleep matters.
Behavioral health matters.
Relationships matter.
The environment matters.
The support structure matters.
The architecture surrounding the individual often determines whether success is temporary or sustainable.
If the last decade was largely about proving that obesity medications can work, the next decade may be about learning how to build systems that help people succeed with them.
How do we preserve muscle and function?
How do we help people maintain gains when life becomes difficult?
How do we support patients when insurance coverage changes?
How do we create employer programs that generate long-term value rather than short-term weight loss?
How do we welcome people back when they struggle instead of treating setbacks as failure?
These are the questions I believe will define the next era of obesity medicine.
The real opportunity
The arrival of therapies such as Foundayo and retatrutide should create excitement.
It should also create perspective.
Scientific discovery is accelerating.
Patient awareness is accelerating.
Access is expanding.
Yet obesity remains what it has always been: a chronic, multifactorial disease requiring long-term management.
The challenge is not simply helping people lose weight.
The challenge is helping people improve their health and quality of life.
What keeps me optimistic is that we are moving away from an era dominated by blame and toward one increasingly grounded in biology, evidence, partnership, and support.
That is good for patients.
It is good for clinicians.
It is good for employers.
And it is good for healthcare.
The medications matter.
The systems matter.
The relationships matter.
And ultimately, the people we serve matter most.
The next era of obesity medicine will not be defined solely by what the medications can do.
It will be defined by how well we help people succeed with them.